Loading…
← CockpitCompetitor Analysis › AJANTPHARM.NS Ajanta PharmaOpen in the cockpit ↗

Ajanta PharmaAJANTPHARM.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Branded generic pharma company selling cardiology, ophthalmology and dermatology drugs across India, Africa and Asia.

≈ A branded-generics exporter to emerging marketsMomentum neutral 40
Mkt cap
$4.38B
US dollars, full cap
Free float
37%
of shares outstanding
$/day
$6.67M
20-day average traded
Fwd P/E
31.7×
forward earnings
ROIC−WACC
+14.8 pp
WACC 12.5%
Hurdle
+10 pp
Req g minus delivered
Next earnings
77 days
3 Feb 2027
Close · INR₹3,274
1D-1.2%
1W-1.4%
1M-0.8%
3M-11.7%
6M+0.8%
YTD+18.2%
1Y+27.5%
ATR %3.1%
Beta0.42
52w lowhigh13.8% off high

What Ajanta Pharma does

Branded generic pharma company selling cardiology, ophthalmology and dermatology drugs across India, Africa and Asia.

Doctors prescribe its off-patent drugs by brand name, so a large field sales force and prescriber loyalty carry the business. A smaller US generics arm, sold on price to wholesalers and pharmacy chains, sits beside the branded business in India, Africa and Asia. The founding Agrawal family controls the company.

In one line: A branded-generics exporter to emerging markets.

Products and services

  • Cardiology/dermatology brands
  • Ophthalmology products
  • Africa branded generics

Customers

  • Doctors/pharmacies in India
  • African healthcare distributors
  • Asian emerging markets

Where it sits in the supply chain

  • Formulation R&D
  • Manufacturing
  • Branded generics distribution…

What could go right

  • Emerging market branded generics growth
  • New product launches

What could go wrong

  • Currency risk in Africa markets
  • Government price controls in India

Moat: narrow (brand, distribution). Strong branded-generic distribution network in Africa and India built over decades.

Headquarters: Mumbai, India · Founded: 1973 · Employees: 13,206

Named competitors

Ajanta Pharma at a glance

Size Ajanta Pharma (AJANTPHARM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $4.38B, the 228th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹3,274 on 18 Nov 2026.

Performance Over six months the shares gained 0.8%, against +10.4% for the median peer and +3.8% for the India market (cap-weighted) — 10th lowest of 20 in its peer set.

Growth Revenue grew 25.0% over the last twelve months (peer median +5.8%); the operating margin is 25.4% (peer median 15.7%).

Valuation It trades at 31.7× forward earnings against a peer median of 29.9× (7th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 14.8 points above its cost of capital (12.5% WACC).

Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 111AJANTPHARM.NS 103
Six months, rebased to 100: Ajanta Pharma against the median of its 20 peers (local-currency closes).

Ajanta Pharma financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹62.2B₹54.3B₹46.2B₹41.8B₹37.3B
Revenue growth—+18%+10%+12%—
Gross profit₹33.0B₹25.2B₹20.7B₹18.7B₹15.4B
EBITDA₹17.6B₹15.0B₹12.6B₹11.8B₹8.41B
Net income₹12.6B₹10.6B₹9.20B₹8.16B₹5.88B
Free cash flown/a₹1.97B₹8.66B₹6.56B₹6.15B
Capital expendituren/a₹3.65B₹3.18B₹1.52B₹1.83B
Total debt₹1.54B₹2.60B₹474M₹353M₹356M

Quarterly statements and history in the cockpit →

Ajanta Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-25%0%+25%600566CAMX002294600332IONS4536000100EMCUREGLAXODFTXTVTXERAS128940600085688336IPCALAB326030AJANTPHARM.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Ajanta Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%20×30×40×600566CAMX002294600332000100EMCUREGLAXOTVTX600079600085688336IPCALABPTCT326030AJANTPHARM.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ajanta Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%+100%0%50%100%600566CAMX0022946003324536EMCUREGLAXOTVTX600079301569688336PTCT326030AJANTPHARM.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ajanta Pharma is the large dot.

Ajanta Pharma competitors and peer comparison

Head to head with its named competitors (AJANTPHARM.NS vs SUNPHARMA.NS vs CIPLA.NS vs TORNTPHARM.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ajanta Pharma AJANTPHARM.NS$4.38B+1%+25%25%31.7×23.8%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%
Torrent Pharmaceuticals TORNTPHARM.NS$18.8B+3%+42%22%70.2×37.6%

How Ajanta Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ajanta Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureAJANTPHARM.NSPeer medianRank in peer set
1-month return-0.8%-2.9%10th highest of 21
6-month return+0.8%+10.4%10th lowest of 20
Distance from 52-week high-13.8%-32.7%7th highest of 21
Revenue growth (TTM)+25.0%+5.8%4th highest of 19
Operating margin25.4%15.7%7th highest of 19
Forward P/E31.7×29.9×7th most expensive of 17
Growth the price implies (Req g, 7 yrs)23.8%5.7%3rd most demanding of 17
Growth delivered (Del g)+13.8%+8.6%6th highest of 17
Hurdle (Req g minus delivered)+10.0 pp-5.0 pp3rd most demanding of 17
ROIC minus cost of capital+14.8 pp+4.9 pp5th highest of 18
EV / EBITDA22.9×21.5×5th most expensive of 11
Net debt / EBITDA-0.3×-0.8×5th most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
Guangzhou Baiyunshan Pharmaceutical 600332.SSChina$4.45B-13%+1%3%12.9×-0.7%+4.7%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%16.7×-5.0%+3.2%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%

Questions

Who are Ajanta Pharma's main competitors?
Named competitors: Sun Pharma (SUNPHARMA.NS), Cipla (CIPLA.NS), Torrent Pharma (TORNTPHARM.NS). The cockpit's measured peer set (industry) also includes HUBEI JUMPCAN PHARMACEUTICAL (600566.SS), Camurus (CAMX.ST), Shenzhen Salubris Pharmaceuticals (002294.SZ), Guangzhou Baiyunshan Pharmaceutical (600332.SS), Ionis Pharmaceuticals (IONS), Santen Pharmaceutical (4536.T).
Is Ajanta Pharma expensive compared with its peers?
On forward p/e it trades at 31.7× against a peer median of 29.9×, 7th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Ajanta Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +0.8% against +10.4% for the median peer; over one year +27.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.